CP was correct the Microsoft of Biotechnology and even Lockheed Martin REQUIRES PS Targeting and Xencor David Szymkowski KNOWS 100%
_________
Patents by Inventor Svetlana Monakhova BACHMANN
Svetlana Monakhova BACHMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD Publication number: 20170128891 Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle. Type: Application Filed: January 19, 2017 Publication date: May 11, 2017
Applicant: Lockheed Martin Corporation
Inventors: Svetlana Monakhova Bachmann, Paul Declan Mountcastle, Byron W. Tietjen
Byron W Tietjen ties to SonosBio and Keystone etc etc ... brings us CLOSER to Xencor and John Springs Stafford LIED it seems to Avid Bioservices CDMO shareholders so who sent him over to divert the IP to Oncologie Inc ?
... some are trying stealthy maneuvers to hide PS Targeting that is required for many Graphene Based Material things ...
________
Contact Information Sonosbio Inc 7503 Jones Ave NW Seattle, WA 98117 Contact: Raymond Tesi Title: Chief Executive Officer Phone: (510) 396-5709 Website: Sonosbio Inc is the only company located at 7503 Jones Ave NW, Seattle, WA 98117
Dr. Tesi has been Chairman since the formation of the Company in September 2015. Since December 2016, Dr. Tesi has been a Director of Savant HWP, an addiction medicine company. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.
Dr. Tesi's significant experience with our licensed technology and his experience as a transplant surgeon, entrepreneur, investor and director of start-up biopharmaceutical companies were instrumental in his selection as a member of the Board of Directors.
David Szymkowski, PhD
David E. Szymkowski leads the immunology group as Vice President of Cell Biology at Xencor Inc where he is focused on translational development of Fc-engineered and bispecific antibodies for the treatment of autoimmune diseases, allergic diseases, and cancer. Prior to joining Xencor in 2002, Dr. Szymkowski was a principal scientist in the respiratory group at Roche Bioscience in Palo Alto, CA. Previously, he was a virology program leader at Roche Pharmaceuticals in the U.K. With 25 years of big pharma and biotech R&D experience at Roche and at Xencor, Dr. Szymkowski has been instrumental in 10 IND submissions, coauthored over forty papers and reviews, is an inventor on over a dozen patents, and speaks frequently on the development of antibody therapeutics and other biologics. Dr. Szymkowski has contributed to the advancement of numerous antibody drugs into clinical trials for lupus, asthma, allergy, and hematological and solid tumors. He received his B.A. at Johns Hopkins University and his Ph.D. in molecular and cell biology from Penn State, and completed a postdoc at the Imperial Cancer Research Fund (U.K.).
_______
The list is long and puzzle pieces ALL going to shine
Avid Bioservices CDMO shareholders best SEND in complaints to SEC DOJ FBI FDA and news organizations ...some are trying very hard to keep things quiet
News 
Market Data 
Discover 
